Patents Assigned to Genitope Corporation
-
Patent number: 7419660Abstract: The present invention provides multivalent vaccines for the treatment of B-cell malignancies (e.g., lymphomas and leukemias). The present invention also provides methods for the production of custom vaccines, including multivalent vaccines for the treatment of immune cell tumors malignancies as well as methods of treating immune cell tumors using custom vaccines.Type: GrantFiled: August 9, 1999Date of Patent: September 2, 2008Assignee: Genitope CorporationInventor: Dan W. Denney, Jr.
-
Patent number: 7405060Abstract: The present invention provides multivalent vaccines for the treatment of B-cell malignancies (e.g., lymphomas and leukemias). The present invention also provides methods for the production of custom vaccines, including multivalent vaccines for the treatment of immune cell tumors malignancies as well as methods of treating immune cell tumors using custom vaccines.Type: GrantFiled: August 9, 2001Date of Patent: July 29, 2008Assignee: Genitope CorporationInventor: Dan W. Denney, Jr.
-
Publication number: 20080116122Abstract: The present invention relates to single-use chromatography devices and systems for use with a durable component for processing compounds such as protein compounds.Type: ApplicationFiled: July 13, 2007Publication date: May 22, 2008Applicant: Genitope CorporationInventors: Scott M. Wheelwright, Steven Schamow, Ed Louie, Andrew T. Zander
-
Publication number: 20070134248Abstract: The present invention provides combination immunotherapy for Non-Hodgkin's Lymphoma. In one embodiment, the combination immunotherapy first provides for the administration of a monoclonal antibody directed to a non-idotypic portion of a lymphoma cell surface immunoglobulin (e.g. a framework region of a variable region). The combination immunotherapy next provides for the administration of an immunogenic composition comprising at least a portion of the same lymphoma cell surface immunoglobulin, whether an idiotypic portion or non-idiotypic portion.Type: ApplicationFiled: December 8, 2005Publication date: June 14, 2007Applicant: Genitope CorporationInventors: Dan Denney, Keri Marie Tate, Thomas P. Theriault
-
Publication number: 20070134249Abstract: The present invention provides combination immunotherapy for Non-Hodgkin's Lymphoma. In one embodiment, the combination immunotherapy first provides for the administration of a monoclonal antibody directed to a non-idotypic portion of a lymphoma cell surface immunoglobulin (e.g. a framework region of a variable region). The combination immunotherapy next provides for the administration of an immunogenic composition comprising at least a portion of the same lymphoma cell surface immunoglobulin, whether an idiotypic portion or non-idiotypic portion.Type: ApplicationFiled: December 8, 2005Publication date: June 14, 2007Applicants: Genitope CorporationInventors: Dan Denney, Keri Tate, Thomas Theriault
-
Patent number: 7208146Abstract: The present invention provides multivalent vaccines for the treatment of B-cell malignancies (e.g., lymphomas and leukemias). The present invention also provides methods for the production of custom vaccines, including multivalent vaccines for the treatment of immune cell tumors malignancies as well as methods of treating immune cell tumors using custom vaccines.Type: GrantFiled: August 9, 2001Date of Patent: April 24, 2007Assignee: Genitope CorporationInventor: Dan W. Denney, Jr.
-
Patent number: 5972334Abstract: The present invention provides multivalent vaccines for the treatment of B-cell malignancies (e.g., lymphomas and leukemias). The present invention also provides methods for the production of custom vaccines, including multivalent vaccines for the treatment of immune cell tumors malignancies as well as methods of treating immune cell tumors using custom vaccines.Type: GrantFiled: December 6, 1996Date of Patent: October 26, 1999Assignee: Genitope CorporationInventor: Dan W. Denney, Jr.
-
Patent number: 5776746Abstract: The present invention provides improved methods for the amplification and expression of recombinant genes in cells. The methods of the present invention permit the isolation of cell lines which have co-amplified input recombinant sequences which encode an amplifiable marker, one or more expression vectors encoding a protein of interest and optionally a selectable marker. The present methods allow the efficient isolation of amplified cell lines which express the protein(s) of interest in a relatively short period of time. The present invention also provides compositions comprising amplified T lymphoid cell lines.Type: GrantFiled: May 1, 1996Date of Patent: July 7, 1998Assignee: Genitope CorporationInventor: Dan W. Denney, Jr.